Shares of Trovagene Inc. (NASDAQ:TROV) traded up 2.3% on Wednesday . The stock traded as high as $5.46 and last traded at $5.33, with a volume of 117,342 shares. The stock had previously closed at $5.21.

Several analysts have weighed in on the stock. Piper Jaffray Cos. reaffirmed a “hold” rating and set a $5.00 price objective (down from $8.00) on shares of Trovagene in a research note on Thursday, May 12th. Leerink Swann reaffirmed a “hold” rating on shares of Trovagene in a research note on Thursday, May 12th. Argus lowered shares of Trovagene from a “buy” rating to a “hold” rating in a research report on Thursday, April 28th. Zacks Investment Research upgraded shares of Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, Maxim Group reiterated a “buy” rating on shares of Trovagene in a research report on Monday, June 6th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $7.13.

The firm’s market cap is $148.32 million. The firm’s 50-day moving average is $5.29 and its 200 day moving average is $4.99.

Trovagene (NASDAQ:TROV) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.03. Equities research analysts predict that Trovagene Inc. will post ($1.33) EPS for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.